UNASSIGNED: Recently, the number of the studies on the relationship between the total @entity648 level (TBL) and @entity2316 ( @entity2316 ) is increasing, but their results were not consistent. Therefore, we performed a meta-analysis to analyze the relationship between TBL and the risk of @entity2316 .We searched 5 databases before October 31, 2016, and reviewed the reference list of relevant articles. The fixed or random-effects model was used to pool risk estimates. We conducted the dose-response meta-analysis to evaluate the relationship between TBL and the risk of @entity2316 .Our meta-analysis showed that TBL in the @entity2316 group was lower than that in @entity2316 (NDN) group (standard mean difference [SMD]: -0.63, 95% CI: -0.80, -0.46). The result of each subgroup also showed that TBL in the @entity2316 group was lower than that in the NDN group. The result of meta-regression indicated that duration of @entity6 might be the source of heterogeneity. Our meta-analysis also showed that there was a significant negative relationship between TBL and the risk of @entity2316 (OR: 0.86, 95%CI: 0.82, 0.90). The results of subgroup analysis were similar to those of SMD; no sources of heterogeneity were detected by meta-regression. Sensitivity analysis indicated that the results were robust. We observed a linear association between TBL and the risk of @entity2316 , and there was a negative dose-response association between TBL and the risk of @entity2316 .In conclusion, @entity648 may be used as a biomarker of @entity2316 . It helps early diagnosis and effective therapeutic strategies on @entity2316 .

Total @entity648 level may be a biomarker of nephropathy in XXXX : A meta-analysis of observational studies based on MOOSE compliant.

@entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetic nephropathy', 'diabetes without the kidney disease', 'DN'] @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']
@entity6 :: (MESH:D003920,Disease) :: ['type 2 diabetes mellitus']
